Core Insights - Shanghai's biopharmaceutical industry is experiencing significant growth, with the scale projected to increase from 761.714 billion yuan in 2021 to 984.702 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 8.94% [1] - The biopharmaceutical manufacturing output is expected to rise from 171.2 billion yuan in 2021 to 201.167 billion yuan by 2024, with a CAGR of 6.9% [1] - By the end of 2024, Shanghai is anticipated to have 2,183 biopharmaceutical enterprises, covering various sectors including manufacturing, services, and wholesale [1] - Shanghai is home to 19 of the top 20 global pharmaceutical companies and 19 of the top 20 medical device companies, which have established headquarters, production, or R&D centers in the city [1] Industry Development Plans - According to the "14th Five-Year Plan" for the development of Shanghai's biopharmaceutical industry, the city aims to establish a world-class biopharmaceutical industry cluster by 2025, including six industrial parks with over 100 billion yuan in scale [2] - In 2022, Shanghai's three leading industries reached a combined scale of 1.8 trillion yuan, with the biopharmaceutical sector accounting for a significant portion [2] - Shanghai has developed a complete biopharmaceutical industry chain with over 80,000 upstream and downstream enterprises, leading the nation with more than 30 companies listed on the Sci-Tech Innovation Board [2] Innovation and Market Position - In 2024, Shanghai is set to approve seven Class I innovative drugs and 15 Class III innovative medical devices, representing 17.5% and 32.6% of the national total, respectively [2] - The city has seen 15 projects with overseas licensing transactions exceeding 500 million USD, with a total transaction value of 19.83 billion USD, marking a 30.5% year-on-year increase and ranking first in the country [2] - Shanghai is positioned to further advance its biopharmaceutical industry amidst a global restructuring phase, focusing on enhancing the entire chain from basic research to application [2]

Group 1 - The 2025 Shanghai International Biopharmaceutical Industry Week will be held from October 13 to October 17, showcasing the growth of Shanghai's biopharmaceutical industry, which is expected to exceed 1 trillion yuan in 2024 [1][2] - The biopharmaceutical industry in Shanghai has grown from 761.71 billion yuan in 2021 to 984.70 billion yuan in 2024, with a compound annual growth rate of 8.94% [1] - As of the end of 2024, there are 2,183 large-scale biopharmaceutical enterprises in Shanghai, covering various sectors including manufacturing, services, and wholesale [1] Group 2 - Shanghai has established a biopharmaceutical industry mother fund with a total scale of 22.5 billion yuan in 2024 [2] - From 2021 to 2024, the cumulative financing in the biopharmaceutical sector in Shanghai reached 238.37 billion yuan [2] - Shanghai is recognized as an innovation hub for the biopharmaceutical industry in China, with 19 of the top 20 global pharmaceutical companies and medical device companies having their headquarters, production, or R&D centers in the city [1]